Stock analysts at StockNews.com initiated coverage on shares of Trinity Biotech (NASDAQ:TRIB – Get Free Report) in a research report issued to clients and investors on Thursday. The firm set a “sell” rating on the stock.
Trinity Biotech Price Performance
Trinity Biotech stock opened at $0.84 on Thursday. Trinity Biotech has a 12 month low of $0.48 and a 12 month high of $3.55. The company has a fifty day moving average price of $0.65 and a two-hundred day moving average price of $0.95. The company has a market cap of $15.17 million, a PE ratio of -0.37 and a beta of 1.21.
Hedge Funds Weigh In On Trinity Biotech
A hedge fund recently raised its stake in Trinity Biotech stock. Hunter Associates Investment Management LLC boosted its stake in Trinity Biotech plc (NASDAQ:TRIB – Free Report) by 5.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 378,590 shares of the company’s stock after buying an additional 18,780 shares during the period. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 as of its most recent SEC filing. 78.97% of the stock is owned by institutional investors and hedge funds.
Trinity Biotech Company Profile
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
See Also
- Five stocks we like better than Trinity Biotech
- 5 discounted opportunities for dividend growth investors
- Meta Takes A Bow With Q1 Earnings – Watch For Tariff Impact in Q2
- How to start investing in penny stocks
- Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be Cautious
- Insider Buying Explained: What Investors Need to Know
- Palantir Earnings: 1 Bullish Signal and 1 Area of Concern
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
